EXTON, Pa., May 03, 2012 (BUSINESS WIRE) -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces a new syndicated report series entitled LaunchTrends: Omontys. Omontys (peginesatide) is a new once-monthly erythropoiesis-stimulating agent (ESA) for anemia due to chronic kidney disease (CKD) in adult patients on dialysis. LaunchTrends: Omontys surveys will be fielded at one month, three months, six months and twelve months post commercial availability. Each report consists of findings from a quantitative survey with over 75 nephrologists and qualitative interviews (over 15) with a subset of the survey respondents. It is believed that uptake for this product will vary between size of dialysis chains and the hospital settings. Quotas will be implemented to ensure a variety of nephrologists participate in this study.

BioTrends has been following the nephrologists' perception of Omontys in the TreatmentTrends(R): US Nephrology reports since the beginning of 2009. According to the most recent TreatmentTrends survey, almost all nephrologists report a moderate to high interest in Omontys (peginesatide) and they view over 40 percent of their dialysis patients as candidates for treatment.

LaunchTrends: Omontys is a four-wave syndicated report series designed to track physician perception, uptake and the competitive environment of Affymax/Takeda Pharmaceuticals' Omontys post-commercial availability (announced April 24, 2012). The report will also assess trial and use of Omontys, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages and product satisfaction. The first wave of this report will be published on July 13, 2012.

BioTrends will also track the US uptake of Omontys in the quarterly TreatmentTrends: US Nephrology report series with the Q2 2012 report scheduled for release in June 2012. TreatmentTrends: US Nephrology is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com .

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com .

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE: BioTrends Research Group, LLC

        
        BioTrends Research Group, LLC 
        Rob Dubman, 781-993-2592 
        
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
  
        or 
        Decision Resources Group 
        Lisa Osgood, 781-993-2606 
        
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
        

Copyright Business Wire 2012

...